Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Cephalalgia ; 28(1): 9-17, 2008 Jan.
Article in English | MEDLINE | ID: mdl-17888011

ABSTRACT

Ethanol stimulating transient receptor potential vanilloid 1 (TRPV1) on primary sensory neurons promotes neurogenic inflammation, including calcitonin gene-related peptide (CGRP)-mediated coronary dilation. Alcoholic beverages trigger migraine attacks and activation of trigeminal neurons plays a role in migraine. We have investigated in guinea pigs whether ethanol by TRPV1 stimulation causes neurogenic inflammation in the trigeminovascular system. Ethanol-evoked release of neuropeptides from slices of dura mater was abolished by Ca(2+) removal, capsaicin pretreatment and the TRPV1 antagonist, capsazepine. Intragastric ethanol increased plasma extravasation in dura mater, an effect abolished by capsazepine and the NK1 receptor antagonist, SR140333, and caused vasodilation around the middle meningeal artery, an effect abolished by capsazepine and the CGRP receptor antagonist, BIBN4096BS. Vasodilation of meningeal vessels by TRPV1 activation and CGRP release may be relevant to the mechanism by which alcohol ingestion triggers migraine attacks.


Subject(s)
Calcitonin Gene-Related Peptide/metabolism , Ethanol/pharmacology , TRPV Cation Channels/metabolism , Trigeminal Ganglion/blood supply , Trigeminal Ganglion/drug effects , Vasodilation/drug effects , Animals , Dura Mater/blood supply , Dura Mater/drug effects , Dura Mater/metabolism , Guinea Pigs , Male , TRPV Cation Channels/physiology , Trigeminal Ganglion/metabolism , Vasodilation/physiology , Vasodilator Agents/pharmacology
2.
Neurol Sci ; 28 Suppl 2: S89-93, 2007 May.
Article in English | MEDLINE | ID: mdl-17508187

ABSTRACT

Over the last 100 years, the discovery of new analgesics has been a complex and difficult task. However, remarkable progress in the identification of novel molecular targets relevant for pain medicines has been reported. Here we will focus on the neuropeptide calcitonin generelated peptide (CGRP) and its receptors (CGRP-R) because of their role in migraine mechanism and migraine therapy. Recent preclinical and clinical data on the localisation, regulation and plasma levels of CGRP and on the function of CGRP-R will be summarised. The reviewed findings highlight the major function of CGRP in migraine and the use of CGRP-R antagonists as a novel approach for the treatment of migraine attack and, perhaps, as migraine prophylactic medicines.


Subject(s)
Calcitonin Gene-Related Peptide/metabolism , Cerebral Arteries/physiopathology , Migraine Disorders/drug therapy , Migraine Disorders/physiopathology , Nervous System/physiopathology , Neurons, Afferent/metabolism , Receptors, Calcitonin Gene-Related Peptide/metabolism , Vasodilation/physiology , Animals , Calcitonin Gene-Related Peptide/analogs & derivatives , Calcitonin Gene-Related Peptide/antagonists & inhibitors , Calcitonin Gene-Related Peptide Receptor Antagonists , Cerebral Arteries/innervation , Humans , Migraine Disorders/metabolism , Nervous System/drug effects , Nervous System/metabolism , Neurons, Afferent/drug effects , Nociceptors/drug effects , Nociceptors/metabolism , Piperazines/pharmacology , Piperazines/therapeutic use , Quinazolines/pharmacology , Quinazolines/therapeutic use , Vasodilation/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...